Differential β2-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines

Oncotarget

Volumn 5, Issue 20, 2014, Pages 10058-10069

  Gargiulo, Lucía ^a   Copsel, Sabrina ^a,b   Rivero, Ezequiel M ^a   Galés, Céline ^c   Sénard, Jean Michel ^c   Lüthy, Isabel A ^a   Davio, Carlos ^b   Bruzzone, Ariana ^a  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c University Hospital of Toulouse   (France)

Author keywords

Adrenergic receptors; Epinephrine; Human breast cancer cells; Non tumorigenic breast cells

Indexed keywords

ADRENALIN; BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; DEXMEDETOMIDINE; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

AREA UNDER THE CURVE; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; BIOSYNTHESIS; BREAST TUMOR; CELL LINE; DISEASE COURSE; DRUG EFFECTS; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DEXMEDETOMIDINE; DISEASE PROGRESSION; EPINEPHRINE; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; ISOPROTERENOL; MCF-7 CELLS; PHENOTYPE; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84930465517     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2460     Document Type: Article

References (48)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893-2917.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
3. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol. 2012; 9:48-57.
4. Hara MR, Sachs BD, Caron MG, Lefkowitz RJ. Pharmacological blockade of a beta 2AR-beta-arrestin-1 signaling cascade prevents the accumulation of DNA damage in a behavioral stress model. Cell Cycle. 2013; 12:219-224.
5. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr., Trendelenburg U. International Union of Pharmacology nomenclature of adrenoceptors. PharmacolRev. 1994; 46:121-136.
6. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci. 2011; 36:457-469.
7. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012; 18:1201-1206.
8. Carie AE, Sebti SM. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 2007; 26:3777-3788.
9. Perez Pinero C, Bruzzone A, Sarappa MG, Castillo LF, Luthy IA. Involvement of alpha2-and beta2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol. 2012; 166:721-736.
10. Slotkin TA, Seidler FJ. Antimitotic and cytotoxic effects of theophylline in MDA-MB-231 human breast cancer cells. Breast Cancer ResTreat. 2000; 64:259-267.
11. Cakir Y, Plummer HK III, Tithof PK, Schuller HM. Betaadrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol. 2002; 21:153-157.
12. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003; 80:63-70.
13. Strell C, Niggemann B, Voss MJ, Powe DG, Zanker KS, Entschladen F. Norepinephrine Promotes the beta1-Integrin-Mediated Adhesion of MDA-MB-231 Cells to Vascular Endothelium by the Induction of a GROalpha Release. Mol Cancer Res. 2012; 10:197-207.
14. Bruzzone A, Sauliere A, Finana F, Senard JM, Luthy I, Gales C. Dosage-dependent regulation of cell proliferation and adhesion through dual beta2-adrenergic receptor/cAMP signals. FASEB J. 2014; 28:1342-1354.
15. Powe DG, Entschladen F. Targeted therapies: Using betablockers to inhibit breast cancer progression. Nat Rev Clin Oncol. 2011; 8:511-512.
16. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010; 1:628-638.
17. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011; 5:5-23.
18. Vazquez SM, Mladovan AG, Perez C, Bruzzone A, Baldi A, Luthy IA. Human breast cell lines exhibit functional alpha(2)-adrenoceptors. Cancer Chemother Pharmacol. 2006; 58:50-61.
19. Vandewalle B, Revillion F, Lefebvre J. Functional betaadrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol. 1990; 116:303-306.
20. Fernandez N, Gottardo FL, Alonso MN, Monczor F, Shayo C, Davio C. Roles of phosphorylation-dependent and -independent mechanisms in the regulation of histamine H2 receptor by G protein-coupled receptor kinase 2. J Biol Chem. 2011; 286:28697-28706.
21. Badino GR, Novelli A, Girardi C, Di Carlo F. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res. 1996; 33:255-260.
22. Draoui A, Vandewalle B, Hornez L, Revillion F, Lefebvre J. Beta-adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors. Anticancer Res. 1991; 11:677-680.
23. Tubio MR, Fernandez N, Fitzsimons CP, Copsel S, Santiago S, Shayo C, Davio C, Monczor F. Expression of a G protein-coupled receptor (GPCR) leads to attenuation of signaling by other GPCRs: experimental evidence for a spontaneous GPCR constitutive inactive form. Journal of Biological Chemistry. 2010; 285:14990-14998.
24. Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, Zhu WZ, Xiao RP, Lakatta EG, Bouvier M, Hebert TE. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem. 2002; 277:35402-35410.
25. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006; 6:240-248.
26. Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol. 2010; 28:4094-4099.
27. Marchetti B, Spinola PG, Plante M, Poyet P, Follea N, Pelletier G, Labrie F. Beta-adrenergic receptors in DMBAinduced rat mammary tumors: correlation with progesterone receptor and tumor growth. Breast Cancer Res Treat. 1989; 13:251-263.
28. Lüthy IA, Bruzzone A, Pérez Piñero CP. Adrenergic Action in Breast Cancer. Current Cancer Therapy Reviews. 2012; 8:90-99.
29. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ. Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat. 2000; 60:153-166.
30. Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy?. Oncotarget. 2010; 1:466-469.
31. Ahles A, Engelhardt S. Polymorphisms determine betaadrenoceptor conformation: implications for cardiovascular disease and therapy. Trends Pharmacol Sci. 2009; 30:188-193.
32. Park MS, Kim BR, Dong SM, Lee SH, Kim DY, Rho SB. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1alpha expression. Oncotarget. 2014; 5:4935-4944.
33. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973; 51:1409-1416.
34. Cailleau R, Young R, Olive M, Reeves WJ Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst. 1974; 53:661-674.
35. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990; 50:6075-6086.
36. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, Perou CM. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat. 2013; 142:237-255.
37. Gaffney EV. A cell line (HBL-100) established from human breast milk. Cell Tissue Res. 1982; 227:563-568.
38. Tang J, Li Z, Lu L, Cho CH. beta-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013; 23:533-542.
39. Badino GR, Novelli A, Girardi C, Di Carlo F. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res. 1996; 33:255-260.
40. McMorris T, Swain J, Smith M, Corbett J, Delves S, Sale C, Harris RC, Potter J. Heat stress, plasma concentrations of adrenaline, noradrenaline, 5-hydroxytryptamine and cortisol, mood state and cognitive performance. Int J Psychophysiol. 2006; 61:204-215.
41. Powe DG, Voss MJ, Habashy HO, Zanker KS, Green AR, Ellis IO, Entschladen F. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat. 2011; 130:457-463.
42. Bodwin JS, Clair T, Cho-Chung YS. Inverse relation between estrogen receptors and cyclic adenosine 3':5'-monophosphate-binding proteins in hormonedependent mammary tumor regression due to dibutyryl cyclic adenosine 3':5'-monophosphate treatment or ovariectomy. Cancer Res. 1978; 38:3410-3413.
43. Zhang J, Barak LS, Winkler KE, Caron MG, Ferguson SS. A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. Differential regulation of receptor resensitization in two distinct cell types. J Biol Chem. 1997; 272:27005-27014.
44. Cheepala S, Hulot JS, Morgan JA, Sassi Y, Zhang W, Naren AP, Schuetz JD. Cyclic Nucleotide Compartmentalization: Contributions of Phosphodiesterases and ATPBinding Cassette Transporters. Annu Rev Pharmacol Toxicol. 2013; 53:231-253.
45. Nikolaev VO, Bunemann M, Schmitteckert E, Lohse MJ, Engelhardt S. Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res. 2006; 99:1084-1091.
46. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, Fung JJ, Choi HJ, Thian FS, Kobilka TS, Puglisi JD, Weis WI, Pardo L, Prosser RS, Mueller L, Kobilka BK. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature. 2010; 463:108-112.
47. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG, Russel FG, Shayo C, Davio C. Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem. 2011; 286:6979-6988.
48. Dowdy S, Wearden S. (1983). Statistics for research. New York, John Wiley & Sons, Inc).